Scarica l'app Stockscreener
77.86
3.06%
-2.46
Dopo l'orario di chiusura:
77.80
-0.06
-0.08%
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Dianthus Therapeutics launches $400M stock offering - Investing.com Nigeria
Integral Health Asset Management Acquires 150,000 Shares in Dianthus Therapeutics - National Today
Integral Health Asset Management LLC Buys New Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics EVP Sells $2.76M in Stock - National Today
Dianthus therapeutics CAO sells shares for $3.56 million By Investing.com - Investing.com Australia
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 43,682 Shares of Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells 122,918 Shares - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock - MarketBeat
Dianthus therapeutics CEO Garcia sells $10m in shares - Investing.com
Dianthus therapeutics CAO sells shares for $3.56 million - Investing.com India
Dianthus Therapeutics announces proposed $400 million public share offering - MSN
Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million - Investing.com
Dianthus Therapeutics Executives Sell Off Significant Shares - TradingView
Dianthus Therapeutics closes $719M public offering By Investing.com - Investing.com Australia
Assessing Dianthus Therapeutics (DNTH) Valuation After Early CAPTIVATE GO Decision And Premium P/B Multiple - simplywall.st
Dianthus Therapeutics (DNTH) CEO sells 122,918 shares after option exercise - Stock Titan
Dianthus Therapeutics closes $719M public offering - Investing.com South Africa
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision - Yahoo Finance
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Bitget
Biotech Dianthus raises $719M to push autoimmune disease drugs - Stock Titan
Dianthus Therapeutics Launches $81-Per-Share Offering; Net Proceeds Expected at $673.5 Million - TradingView
Dianthus Therapeutics Announces Major Public Equity Offering - TipRanks
Q1 EPS Estimate for Dianthus Therapeutics Reduced by Analyst - MarketBeat
Midtown drug company to sell up to $625M in stock to fund autoimmune research - Crain's New York Business
Dianthus Therapeutics (DNTH) offers 7.31M shares, $624.9M gross - Stock Titan
Best Biotech Stocks To ConsiderMarch 11th - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading Volume After Analyst Upgrade - MarketBeat
Biotech Dianthus prices $625M deal to advance autoimmune drugs - Stock Titan
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - Bitget
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Dianthus Therapeutics says co. prices upsized offering of 7,313,582 shares at $81.00 per share - marketscreener.com
Dianthus Therapeutics Announces Pricing of $625 Million Upsized Public Offering of Common Stock - Quiver Quantitative
Dianthus Therapeutics Says Co. Prices Upsized Offering Of 7,313,582 Shares At $81.00 Per Share - TradingView
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - GlobeNewswire Inc.
Dianthus Therapeutics’ CAPTIVATE Trial Sparks Renewed Investor Interest - timothysykes.com
Surge in Dianthus Therapeutics Stock Amid Positive Trial Results - StocksToTrade
DNTH Stock Jumps 21.5% Despite Wider-Than-Expected Q4 Loss as Pipeline Prospects Fuel Rally - AlphaStreet
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating (DNTH) - Seeking Alpha
AutoZone To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Raised to Strong-Buy at Raymond James Financial - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $80.00 - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat
Guggenheim reiterates buy rating for Dianthus Therapeutics (DNTH) - MSN
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) - Finviz
Investment firm Raymond James announced an upgrade of biopharmaceutical company Dianthus Therapeutics Inc. (DNTH) stock rating from "Outperform" to "Strong Buy". - Bitget
Beyond the Balance Sheet: What SWOT Reveals About Dianthus Thera - GuruFocus
Raymond James upgrades Dianthus Therapeutics (DNTH) - MSN
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Dianthus Therapeutics Hits New 1-Year High After Analyst Upgrade - National Today
AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks - TipRanks
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Cowen Maintains Buy on DNTH and Oppenheimer Keeps Outperform March 2026 - Meyka
Dianthus Therapeutics, Inc. (DNTH) Discusses Interim Responder Analysis and Early Go Decision for CAPTIVATE Trial in CIDPSlideshow (NASDAQ:DNTH) 2026-03-09 - Seeking Alpha
Clear Street raises Dianthus Therapeutics price target on CIDP trial data - Investing.com Canada
Guggenheim’s Bold Move: Price Target for Dianthus Doubles to $200 - timothysykes.com
Dianthus Therapeutics announces proposed $400 million underwritten public offering - marketscreener.com
Dianthus Therapeutics Announces Proposed $400 Million Underwritten Public Offering - TradingView
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering - Bitget
Dianthus Therapeutics shares fall 5% after announcing $400 million stock offering - Investing.com Canada
Jefferies raises Dianthus Therapeutics stock price target on CIDP trial progress - Investing.com Canada
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):